# The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

> **NCT04985968** · PHASE3 · TERMINATED · sponsor: **InDex Pharmaceuticals** · enrollment: 171 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Cobitolimod 250 mg
- **DRUG:** Cobitolimod 500 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04985968
- **Lead sponsor:** InDex Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-24
- **Primary completion:** 2023-12-20
- **Final completion:** 2023-12-20
- **Target enrollment:** 171 (ACTUAL)
- **Why stopped:** Due to futility
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04985968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04985968, "The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04985968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*